Purpose: The aim of this study was to demonstrate a new model for implementing a transit dosimetry system as a means of in vivo dose verification with a water equivalent electronic portal imaging device (WE-EPID) and a conventional treatment planning system (TPS). Method and materials: A standard amorphous silicon (a-Si) EPID was modified to a WE-EPID configuration by replacing the metal-plate/phosphor screen situated above the photodiode detector with a 3 cm thick water equivalent plastic x ray converter material. A clinical TPS was used to calculate dose to the WE-EPID in its conventional EPID position behind the phantom/patient. The "extended phantom" concept was used to facilitate dose calculation at the EPID position, which is outside the CT field of view (FOV). The CT images were manipulated from 512 9 512 into 1024 9 1024 and padded pixels were assigned the density of air before importing to the TPS. The virtual WE-EPID was added as an RT structure of water density at the EPID plane. The accuracy of TPS dose calculations at the EPID plane in transit geometry was first evaluated for different field sizes and thickness of object in the beam by comparison with the dose measured using a 2D ion chamber array (ICA) and the WE-EPID. Following basic dose response tests, clinical fields including direct single fields (open and wedged) and modulated fields (integrated or control point by control point doses for VMAT) were measured for 6 MV photons with varying of solid water thickness or an anthropomorphic phantom present in beam. The EPID images were corrected for dark signal and pixel sensitivity and converted to dose using a single dose calibration factor. The 2D dose evaluation was conducted using 3%/3 and 2%/2 mm gamma-index criteria. Results: The measured dose-response with the ICA and WE-EPID for all basic dose-response tests agreed with TPS dose calculations to within 1.5%. The maximum difference in dose profiles for the largest measured field size of 25 9 25 cm 2 was 2.5%. Gamma evaluation showed at least 94% (3%/ 3 mm criteria) and 90% (2%/2 mm) agreement in both integrated and control-point doses for all clinical fields acquired by the WE-EPID and ICA when compared with TPS-calculated portal dose images. Conclusion: A new approach to transit dose verification has been demonstrated utilizing a water equivalent EPID and a commercial TPS. The accuracy of dose calculations at the EPID plane using a commercial TPS beam model was experimentally confirmed. The model proposed in this study provides an accurate method to directly verify doses delivered during treatment without the additional uncertainties inherent in modelling the complex dose-response of standard EPIDs.
INTRODUCTION
The current trend of radiation therapy (RT) is moving toward increasingly precise and accurate dose delivery, which employs radiation beam intensity-modulation for dose sculpting and image guidance for target positioning. Modulated beams often contain complex fluence maps with large dose gradients that are tailored to each individual patient and bear little resemblance to standard fields used for commissioning beam models. Factors that could lead to differences between the delivered and planned dose distributions include (a) anatomical changes (e.g., changes in tumor size and shape, patient weight and organ motion 1, 2 ) (b) treatment delivery issues (e.g., MLC calibration offsets 3, 4 ) and (c) limitations in TPS beam model accuracy. 5, 6 In addition to these uncertainties in treatment accuracy, there are more serious failure modes that can lead to errors in treatment, such as corrupted data or equipment malfunction. In response to increasing treatment complexity, quality assurance (QA) bodies throughout the world acknowledge that patient treatment verification using in vivo dosimetry is highly desirable for optimal patient safety during radiation treatment. [7] [8] [9] The use of Electronic Portal Imaging Devices (EPIDs) for detecting various dose delivery errors has been demonstrated in previous studies. [10] [11] [12] Bojechko et al. quantified the effectiveness of EPID-based dosimetry in detecting clinical incidents such as changes in the machine output, corrupted plans and patient positioning errors occurring during setup. 10 The authors reported that 74% of 229 high severity incidents reported over a 2.5 yr period could be detected using in vivo first-fraction EPID dosimetry, compared to just 6% when using pre-treatment EPID dosimetry. It is clear that in vivo portal dosimetry has the potential to improve safety in radiotherapy.
It is also important to understand the limitations of portal dosimetry. One weakness of portal dosimetry with standard EPIDs is that these devices cannot measure dose in water directly since the measured signal is primarily proportional to the energy absorbed in the high atomic number Gd2O2S:Tb phosphor scintillator. 13, 14 Therefore, current portal dosimetry models do not provide a direct comparison of the measured dose and the prescribed dose because they include a series of calculations that model the conversion of the EPID image to dose in water. For patient dose reconstruction based on portal images acquired during treatment, there is also a need to back-project the fluence and to model the primary and scatter dose contributions for a given patient geometry. The accuracy of these portal dosimetry systems should be benchmarked against direct dose in water measurements that reflect clinical applications as closely as possible. 15 Agreement between portal dosimetry and TPS calculation alone does not validate the accuracy of either model and could in principle mask systematic errors in the TPS model or the dose delivery. The degree to which these issues undermine the reliability of a given portal dosimetry implementation is difficult to establish, particularly outside of well-resourced academic departments.
One way of more directly relating the EPID measurement to the TPS calculation may be to calculate dose to the EPID within the TPS itself. The "extended phantom" concept calculates a predicted dose image (PDI) at the EPID plane using the TPS dose in water model and has been demonstrated by several groups. [16] [17] [18] [19] The accuracy of the PDI calculated by the TPS convolution/superposition model is expected to decrease with decreasing air gap between the object and EPID plane because the increasing relative contributions from multiple-scattered photons reaching the detector plane are not modelled. 17 The TPS-calculated PDI accuracy should improve at larger air gaps, where the dose is dominated by primary and single-scatter photons. 17 However, previous studies confirm that the current standard a-Si EPID is not water equivalent and that additional corrections are required before one can compare the TPS-calculated dose in water and the EPID measurement, thereby again breaking a direct link between TPS dose calculation and measurement.
This problem can be resolved with access to a water equivalent EPID (WE-EPID). Our group has been involved in the development of three different WE-EPID designs, all based on a-Si photodiode arrays identical to those in current standard EPIDs; prototype (a) replaces the metal screen and phosphor scintillator with solid water (Direct EPID) prototype, [20] [21] [22] (b) combines a standard EPID and a dosimetry array device in a dual-layer approach, 23 prototype (c) replaces the metal screen and phosphor scintillator with a plastic scintillator fibre array (PSFA). 24 Each of these prototypes has been benchmarked against reference dose in water measurements to within 2% over a wide range of clinical dosimetry scenarios (both transit and non-transit). Prototype (a) suffers from insufficient signalto-noise for MV imaging with low doses. 25 Prototype (b) overcomes this problem by decoupling the imaging and dosimetry detectors. Prototype (c) overcomes this problem by careful design of a water equivalent scintillator for simultaneous imaging and dosimetry with a single detector. The optimization and implementation of WE-EPIDs is the topic of ongoing research by our group. 26, 27 Because we have previously demonstrated the near dosimetric equivalence of prototypes (a), (b), and (c), for the purposes of this study measurements and TPS calculations were only performed using prototype (a).
In this study, we present the first demonstration of a clinical portal dosimetry model combining a WE-EPID and the "extended phantom" concept. This is the first a-Si EPID based in vivo dosimetry model that provides direct comparison between dose in water measurement and TPS-calculated dose, with no separate modelling required. This represents a significant improvement in the implementation of portal dosimetry and supports the potential of WE-EPIDs as an alternative to current EPID imaging panels.
METHODS AND MATERIALS

2.A. Equipment
2.A.1. Water equivalent EPID (WE-EPID)
The EPID device used was based on a standard a-Si EPID (XRD 1640 AN CS PerkinElmer, Santa Clara, CA, USA) and the imaging data was collected using XIS software V3.3.1.1 (PerkinElmer, Santa Clara, CA, USA). The EPID was modified into a WE-EPID with 3 cm of water equivalent buildup material in place of the copper sheet and Gd202S phosphor screen components of standard clinical EPIDs (see Fig. 1 ). 20 The WE-EPID configuration used either 30 9 30 9 3 cm 3 (Gammex RMI, Middleton, WI, USA) or 40 9 40 9 3 cm 3 (CIRS, Norfolk, VA, USA) of solid water buildup and has been demonstrated to be water equivalent to within 1.5%. 20, 21 To validate the TPS "extended phantom" concept over a wide range of clinical scenarios and field sizes, all treatment fields as described in Section 2.C were measured with the WE-EPID, as well as with a reference 2D array dosimeter (see the following Section 2.A.2.).
2.A.2. Reference 2D dosimeter
The I'mRT MatriXX 2D ionization chamber array (ICA) and accompanying OmniPro-I'mRT software (version 1.6, IBA Dosimetry, Schwarzenbruck, Germany) was used as the reference dosimeter [ Fig. 1(c) ]. All the ICA measurements were performed at 3 cm depth to match the WE-EPID setup.
2.A.3. Treatment planning system
All radiation fields described below were planned using a clinical Pinnacle TPS (Pinnacle, v9.10, Philips Medical Systems, Fitchburg, WI, USA) and calculated using the adaptive convolution/superposition dose algorithm. 28 We adapted a similar "extended phantom" approach as described in previous studies [17] [18] [19] to modify the image FOV (Fig. 2) . The CT images were processed by adding "padded" pixels to extend the image FOV from 512 9 512 pixels to 1024 9 1024 pixels using in-house software written in Matlab (version: 7.10.0.499 (R2010a), Mathworks Inc., MA, USA) before importing them into the TPS. The size of individual pixels was not altered. The padded image pixels were assigned CT numbers corresponding to air. Extending the FOV was required to incorporate the EPID as an RT structure with dimensions 4 9 40 9 40 cm 3 at 150 cm source to detector distance (SDD). The EPID structure was assigned a uniform density of 1.0 g cc À1 to match that of water (Fig. 2) . This allowed the TPS to perform dose calculations outside of the scanned CT FOV. The TPS-calculated planar dose was exported at the EPID detector plane for each field.
2.B. EPID image corrections and dose calibration
All acquired EPID images were dark field and flood field corrected. The flood field correction removes the variation in pixel-to-pixel sensitivity as well as the beam intensity profile information from the image. To restore the beam profile, a pixel sensitivity map (PSM) was measured using a multiple field calibration method described previously. 29 The PSM contains only the inherent differences in sensitivity of the individual pixels in the imaging matrix, specified relative to the central pixel. Each EPID image was processed using inhouse Matlab code to restore beam profile information using a similar methodology to that described in a previous study. 30 The corrected WE-EPID pixel values were calibrated to dose by cross-calibration with the ICA. The reference conditions used for cross-calibration were 10 9 10 cm 2 field size, 150 cm SDD and 20 cm of solid water positioned on the treatment couch centered at the isocenter. A pixel-to-dose calibration factor and PSM was applied to each EPID image to convert it to a dose image. The same principle of calibration was applied to the ICA, with a dose calibration established from a calibrated Farmer chamber and a vendor supplied pixel sensitivity map. 
2.C. Dose-response evaluation
Basic dose-response tests for different field sizes, off axis ratios and transmission factors were performed. The dose-response measured with the WE-EPID and ICA was directly compared to the TPS-calculated dose at the WE-EPID plane to verify the accuracy of the clinical TPS beam model under transit dosimetry conditions. To assess the limitations of the TPS model under the extended phantom geometry, we compared the TPS-calculated open square field size output factor and the offaxis dose-response at SDDs of 120 and 130 cm in addition to SDD 150 cm with ICA measurements. The TPS model used was a standard clinical model commissioned according to standard guidelines. 31, 32 We also compared beam profiles for the largest field size of 25 9 25 cm 2 with varying thickness of object in the beam (0, 10, 20, 30 and 40 cm solid water slab). All the field size dimensions reported in this work describe the field width as defined at the isocenter, unless stated otherwise. The maximum field size exposure is restricted to ensure that electronic readout components were not irradiated, as per the recommendations for standard EPID use. 
2.C.2. IMRT fields
Twenty clinical IMRT cases were measured with either 20 or 40 cm thick solid water slab or an anthropomorphic phantom in the beam. The clinical IMRT cases consisted of four modulated fields from brain plans and sixteen modulated fields from prostate cases (out of sixteen clinical fields, seven were from intact prostate plans having low modulation while nine clinical fields were from prostate plans with involved pelvic nodes covering treatment areas at least 20 cm in width). All these plans were planned using step and shoot delivery only.
2.C.3. VMAT field
Three clinical VMAT cases were measured with either 20 cm thick solid water slab or an anthropomorphic phantom in the beam. The clinical VMAT cases included one intact prostate plan (single full arc with low modulation) and two head and neck plans (planned with two arcs covering a treatment area approximately 23 cm in width). The measured and calculated doses were evaluated with all control points (CP) collapsed to gantry zero. To compare time-resolved measurements to predicted dose, the measured dose was sampled at the correct frequency to match the TPS-calculated dose per control point. The EPID data was acquired in free running mode unsynchronized with linac gun pulses. Using a priori knowledge of monitor units and dose rate from the DICOM RTPLAN for each control point, the number of expected EPID frames per control point could be determined. The EPID frames were then resampled into integrated CP images following the method described by Podesta et al. 33 The treatment couch was modelled in the TPS. All experiments were conducted on an Elekta Synergy linear accelerator (Elekta Oncology Systems, Crawley, UK) with Agility MLC and 6 MV photons at gantry 0 0 or 90 0 only. The gamma evaluation technique 34 was applied to compare the 2D dose maps measured with the WE-EPID, ICA and calculated with the TPS. The gamma criteria used was 2% and 3% dose difference (relative to the maximum dose) and 3 and 2 mm distance-to-agreement, respectively, with doses below 10% of the maximum dose excluded from the evaluation. Figure 4 compares the WE-EPID and ICA measured doseresponse with TPS-calculated dose-response for varying square field sizes and transmission through solid water slabs of varying thickness. The measured dose-response for all tests agreed with the TPS-calculated dose-response to within 2%, suggesting the clinical beam model predicts transit dose accurately at the EPID plane. Figure 5 compares the measured beam profiles with 30 and 40 cm of solid water thickness for open 25 9 25 cm 2 fields with TPS-calculated profiles. The relative profile agreements are also summarized in Table I . The off axis response measured at SDD 130 and 150 cm showed better agreement with TPS-calculated data compared to the measurement performed at SDD 120 cm (Figs. S1 and S2).
RESULTS
3.A. Dose-response evaluation
3.B. Clinical field
3.B.1. Open and wedge fields with heterogeneous phantoms
The transit dose images measured with WE-EPID, ICA and calculated with the TPS for direct single field (described in Section 3.C.1.) using an anthropomorphic phantom (open or wedged) and an inhomogeneous slab phantom (open field) are displayed in Fig. 6 . The gamma evaluation of the dose images acquired with the WE-EPID versus those measured with the TPS, ICA versus TPS and ICA versus WE-EPID for all fields showed at least 95.5% and 91.5% agreement for 3%/3 and 2%/2 mm criteria, respectively. Similarly, the average gamma values were between 0.31 and 0.36 for gamma criteria 3%/3 mm and 0.36-0.45 between 2%/2 mm among all three configurations. Dose profiles passing through a plane in the WE-EPID measured, and TPS-calculated dose images have also been extracted and compared in Figure 6 .
3.B.2. IMRT fields
A summary of the gamma-index pass rates for all modulated fields measured with a 20 or 40 cm solid water slab (homogeneous phantom) and an anthropomorphic phantom placed in the beam is shown in Table II . The gamma-index evaluation of the dose images acquired by the WE-EPID and ICA when compared to those calculated with the TPS for all clinical IMRT fields showed at least 94% and 90% agreement with 3%/3 and 2%/2 mm criteria, respectively, with gamma index <1. The average gamma-index values between 0.34-0.44 and 0.39-0.58 with gamma evaluation criteria of 3%/3 and 2%/2 mm, respectively.
3.B.3. VMAT field
The gamma evaluation of the integrated VMAT dose images acquired by WE-EPID and ICA versus TPS showed greater than 96% (for 3%/3 mm) and 90% (for 2%/2 mm) agreement with gamma index <1. A summary of the gamma-index pass rates for VMAT fields measured with either 20 or 40 cm solid water slab (homogeneous phantom) or an anthropomorphic phantom placed in the beam is shown in Table III . Figure 7 displays the 2D gamma evaluation between the TPS-calculated and measured dose images per control point (for the first three control points). The gamma pass rate for the WE-EPID when compared with ICA and TPS was similar (<0.6%). Figure 8 displays the 2D gamma evaluation between the TPS-calculated and measured dose for integrated images.
DISCUSSION
A simple model for implementing transit dose verification with a WE-EPID as a means of in vivo dosimetry has been demonstrated. The dose measured with a WE-EPID can be directly compared to the dose calculated by the TPS in a clinical treatment plan, replacing the need for a separate EPID model. No additional tuning or corrections of the standard clinical TPS beam model was required when using the extended phantom approach to calculate the dose deposited in the EPID, despite the EPID being positioned at an extended distance beyond the phantom/patient geometry. The TPS dose calculated at the EPID plane showed good agreement with the dose measured by the WE-EPID dosimetry systems and an ion chamber array. The water equivalence of WE-EPIDs has been demonstrated in several studies. [20] [21] [22] This work is the first demonstration of (a) the WE-EPID for VMAT, utilizing the direct EPID prototypes, (b) the accuracy of the Pinnacle TPS model to calculate dose in water at the EPID level, and (c) a simple and robust model for the clinical implementation of WEEPIDs for in vivo dosimetry using the "extended phantom" method. The supplementary data suggest that the convolution/superposition model predicts the dose more accurately at larger air gaps between the patient (object) and WE-EPID, consistent with previous studies. 16, 17 Our results indicate that a modern TPS beam model commissioned according to conventional radiotherapy guidelines 35 may be sufficiently accurate for transit dose calculations for a wide range of clinical scenarios including open, wedged, complex modulated beams, and a range of patient geometries and inhomogeneity. The imaging performance with a WE-EPID is not addressed in this study but is the topic of ongoing studies into optimizing WE-EPID detector designs. 23, 26, 27 For practical setup reasons, this work only included beams at orthogonal gantry angles. Studies at arbitrary gantry angles and translating this work into routine clinical practice will require incorporating the WE-EPID into the linac in place of the standard EPID. The WE-EPID used in this study weighs approximately 2 kg more than standard EPID. There is potential in the design to reduce this total weight if necessary. Any changes in panel sag and gantry angle dependencies may be addressed using existing methods. 36 A process for extracting TPS-calculated doses at the EPID plane for arbitrary gantry angles also needs to be developed. These practical implementation issues are currently being addressed as part of a clinical translation project. We used in-house developed software to conduct the gamma analysis but there are several radiotherapy dosimetry software products that can import and compare TPS and calibrated EPID images and could be used to conduct the analysis, avoiding the need for additional specialized software. Another limitation of this work is that without access to a standard portal dosimetry system we could not make quantitative comparisons between WE-EPID and standard EPID based portal dosimetry. The increased robustness in dosimetry that comes with direct dose in water measurement should minimize false positive and false negative results for a wide range of clinical scenarios and thereby provide a more effective method of treatment verification as treatment delivery becomes increasingly complex.
CONCLUSION
A new approach to transit dose verification is presented utilizing a water equivalent EPID and a commercial TPS. The accuracy of dose calculations at the EPID plane using a commercial TPS beam model was experimentally confirmed. The model proposed in this study provides an accurate method to directly verify doses delivered during treatment without the additional uncertainties inherent in modelling the complex dose-response of standard EPIDs. 
